Navigation Links
bioMETRX New Product to be Sold at Major National Warehouse Club
Date:9/15/2008

roducts, a pattern that the company expects to continue to grow over the next 6 months. The company has generated over $2,000,000 in real product sales revenue over the last 12 months, and has already exceeded its 3rd quarter forecasts.

As the global leader in consumer biometric product engineering, development and sales, bioMETRX's smartTOUCH(TM) technology has proven to be the most dependable and robust consumer biometric platform available today. It's smartTOUCH(TM) product line is making its way into the marketplace directly through the company, as well as through trusted global partners and nationally recognized retailers. The company continues to introduce new and exciting products that are expected to hit retailer shelves over the next three quarters.

About bioMETRX, Inc.

bioMETRX, Inc. is rapidly becoming the global leader in designing and bringing to market, practical, secure, everyday consumer biometric products for the garage door, door hardware, HVAC, home security, PC, automotive and portable lock markets. Utilizing its proprietary technology, the smartTOUCH(TM) platform, bioMETRX has developed an entire family of products so smart, they recognize you. The company's product line is branded under the protected trade name smartTOUCH(TM). bioMETRX also designs and provides personal identification technology to a number of Original Equipment Manufacturers (OEM's).

For more information on bioMETRX and/or the company's smartTOUCH(R) line of products, visit the Company's Web site at http://www.biometrx.net

Safe Harbor Statement: This release may contain certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this release with respect to bioMETRX's business, financial condition or results of operations, as well as matters of timing and the prospective terms of any transaction described a
'/>"/>

SOURCE bioMETRX Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related biology news :

1. bioMETRX, Inc. Retains Global Investment Banking Firm Mesirow Financial, Inc. as Financial Advisor
2. bioMETRX, Inc. Acquires Assets of Sequiam Biometrics (Pty) Ltd.
3. bioMETRX, Inc. Completes Exclusive Licensing Agreement With EZ Print, LLC
4. bioMETRX, Inc. Completes Sequiam Asset Purchase
5. bioMETRX, Inc. Gun Storage Products Endorsed by the Handgun Club of America
6. bioMETRX, Inc. Partners with Biometric Solutions, LLC to Deliver Next Generation Finger Activated Technology
7. bioMETRX, Inc. Garage Door Opener Named Best In Class
8. bioMETRX Expands Engineering and Manufacturing Capabilities
9. bioMETRX, Inc. Files for Several New Patents
10. bioMETRX, Inc. Introduces New Products
11. bioMETRX, Inc. Closes Angel Round of Funding
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Delivering medicine directly into a tumor 2Biogen Idec's oral compound BG-12 achieves development milestones in MS and RA 2Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 62407 1Targeted Breast Ultrasound Can Reduce Biopsies for Women Under Forty 62407 2Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 1Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 2Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 3Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 4Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 5Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 6Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 7Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 8Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 9Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 10Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 11Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 12Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 13Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 14Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 15Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 16Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 17Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 18Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 19Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 20Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 21Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 22Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 23Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 24Significant potential of late and mid stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6664 25Omnetics Announces Newest Addition to Nano Circular Family 62401 1Omnetics Announces Newest Addition to Nano Circular Family 62401 2
Other Biology Technology:The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 2The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 3The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 4The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 5The use of CypHer5E and the IN Cell Analyzer 1000 for live-cell receptor internalization studies 6The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 2The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 3The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 4The development of a calcitonin-gene related peptide (CGRP) receptor-binding assay using the LEADseeker Multimodality Imaging System 5Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 2Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 3Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 4Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 5Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 6Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 7Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 8Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 9Performance of Ad-A-Gene EGFP-MAPKAP-k2: an adenoviral vector gene delivery system 10